Colchicine to Reduce Coronary Artery Inflammation in People With HIV

The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clinical trial. Neither participants nor researchers will know which treatment is assigned during the study. The primary endpoint is the change in coronary artery inflammation measured by coronary computed tomography angiography (CCTA) after 96 weeks.

NCT Number	NCT07704164
Lead Sponsor	Instituto de Investigación Hospital Universitario La Paz Collaborators: Instituto de Salud Carlos III
Conditions	HIV Infection, Cardiovascular Diseases (CVD)
Enrollment	90 participants
Start Date	2026-06
Primary Completion	2028-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-15